174 related articles for article (PubMed ID: 32641577)
1. [Relationship between Drug Metabolism and Intestinal Microbiota in Parkinson's Disease].
Hirayama M; Ohno K; Katsuno M
Brain Nerve; 2020 Jul; 72(7):805-809. PubMed ID: 32641577
[TBL] [Abstract][Full Text] [Related]
2. The link between the gut microbiota and Parkinson's Disease: A systematic mechanism review with focus on α-synuclein transport.
Nielsen SD; Pearson NM; Seidler K
Brain Res; 2021 Oct; 1769():147609. PubMed ID: 34371014
[TBL] [Abstract][Full Text] [Related]
3. The gut microbiome in Parkinson's disease: A culprit or a bystander?
Keshavarzian A; Engen P; Bonvegna S; Cilia R
Prog Brain Res; 2020; 252():357-450. PubMed ID: 32247371
[TBL] [Abstract][Full Text] [Related]
4. The Link between Gut Dysbiosis and Neuroinflammation in Parkinson's Disease.
Baizabal-Carvallo JF; Alonso-Juarez M
Neuroscience; 2020 Apr; 432():160-173. PubMed ID: 32112917
[TBL] [Abstract][Full Text] [Related]
5. Altered gut microbiota and intestinal permeability in Parkinson's disease: Pathological highlight to management.
Sharma S; Awasthi A; Singh S
Neurosci Lett; 2019 Nov; 712():134516. PubMed ID: 31560998
[TBL] [Abstract][Full Text] [Related]
6. Parkinson's Disease and Gut Microbiota.
Hirayama M; Ohno K
Ann Nutr Metab; 2021; 77 Suppl 2():28-35. PubMed ID: 34500451
[TBL] [Abstract][Full Text] [Related]
7. Brain-gut-microbiota axis in Parkinson's disease.
Mulak A; Bonaz B
World J Gastroenterol; 2015 Oct; 21(37):10609-20. PubMed ID: 26457021
[TBL] [Abstract][Full Text] [Related]
8. Emerging disease-modifying strategies targeting α-synuclein for the treatment of Parkinson's disease.
O'Hara DM; Kalia SK; Kalia LV
Br J Pharmacol; 2018 Aug; 175(15):3080-3089. PubMed ID: 29722028
[TBL] [Abstract][Full Text] [Related]
9. The Gut and Parkinson's Disease: Hype or Hope?
Scheperjans F; Derkinderen P; Borghammer P
J Parkinsons Dis; 2018; 8(s1):S31-S39. PubMed ID: 30584161
[TBL] [Abstract][Full Text] [Related]
10. Roles of α‑synuclein in gastrointestinal microbiome dysbiosis‑related Parkinson's disease progression (Review).
Lei Q; Wu T; Wu J; Hu X; Guan Y; Wang Y; Yan J; Shi G
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34414447
[TBL] [Abstract][Full Text] [Related]
11. Gut Microbiota Approach-A New Strategy to Treat Parkinson's Disease.
Liu J; Xu F; Nie Z; Shao L
Front Cell Infect Microbiol; 2020; 10():570658. PubMed ID: 33194809
[TBL] [Abstract][Full Text] [Related]
12. Implications of the Gut Microbiome in Parkinson's Disease.
Elfil M; Kamel S; Kandil M; Koo BB; Schaefer SM
Mov Disord; 2020 Jun; 35(6):921-933. PubMed ID: 32092186
[TBL] [Abstract][Full Text] [Related]
13. The alteration of intestinal mucosal α-synuclein expression and mucosal microbiota in Parkinson's disease.
Shi J; Wang Y; Chen D; Xu X; Li W; Li K; He J; Su W; Luo Q
Appl Microbiol Biotechnol; 2023 Mar; 107(5-6):1917-1929. PubMed ID: 36795141
[TBL] [Abstract][Full Text] [Related]
14. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
15. Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson's Disease.
Caputi V; Giron MC
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29882798
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's disease and the gastrointestinal microbiome.
Lubomski M; Tan AH; Lim SY; Holmes AJ; Davis RL; Sue CM
J Neurol; 2020 Sep; 267(9):2507-2523. PubMed ID: 31041582
[TBL] [Abstract][Full Text] [Related]
17. Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation.
Pal GD; Ouyang B; Serrano G; Shill HA; Goetz C; Stebbins G; Metman LV; Driver-Dunckley E; Mehta SH; Caviness JN; Sabbagh MN; Adler CH; Beach TG;
Mov Disord; 2017 Feb; 32(2):274-277. PubMed ID: 27911008
[TBL] [Abstract][Full Text] [Related]
18. Microbiome, Parkinson's Disease and Molecular Mimicry.
Miraglia F; Colla E
Cells; 2019 Mar; 8(3):. PubMed ID: 30866550
[TBL] [Abstract][Full Text] [Related]
19. The Appendix in Parkinson's Disease: From Vestigial Remnant to Vital Organ?
Killinger B; Labrie V
J Parkinsons Dis; 2019; 9(s2):S345-S358. PubMed ID: 31609697
[TBL] [Abstract][Full Text] [Related]
20. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels.
Gündner AL; Duran-Pacheco G; Zimmermann S; Ruf I; Moors T; Baumann K; Jagasia R; van de Berg WDJ; Kremer T
Neurobiol Dis; 2019 Jan; 121():205-213. PubMed ID: 30236861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
